Myriad Genetics Class Action Lawsuit

Myriad Genetics Class Action Lawsuit

Chimicles Schwartz Kriner & Donaldson-Smith LLP (CSK&D) is investigating a potential class action lawsuit on behalf of Medicare patients that have received a BRCA 1 genetic test from Myriad Genetics. There have been reports that Myriad is categorizing the test as “screening” instead of “diagnostic”, resulting in Medicare denying coverage and patients paying for the test out of pocket. Patients with the BRCA 1 gene have a predisposition to developing breast cancer. The BRCA 1 genetic test is an influential test in determining a patient’s treatment. Myriad Genetics is the sole processor of BRCA 1 genetic tests. CSK&D is investigating reports that Myriad Genetics has improperly denied Medicare coverage, requiring patients to pay out of pocket and is seeking to recover on behalf of those patients.

If you have received a BRCA 1 genetic test from Myriad Genetics and paid out of pocket please use the “Email us about this Case” button to contact the attorneys for this case.

(*) Indicates required field: When communicating with us through this site or otherwise in connection with a matter for which we do not already represent you, your communication may not be treated as privileged or confidential, and does not create an attorney-client relationship between you and our Firm.

Attorneys for this case:

Kimberly M. Donaldson-Smith
Timothy N. Mathews